India, Oct. 23 -- ORIC Pharmaceuticals (ORIC) presented clinical data for enozertinib, an investigational EGFR inhibitor, in patients with previously untreated non-small cell lung cancer (NSCLC) carrying atypical EGFR mutations at the ESMO Congress 2026.
The company plans to advance the drug into a global Phase 3 registrational trial in the first half of 2027.
Enozertinib is an oral, brain-penetrant EGFR inhibitor being developed for NSCLC patients with atypical EGFR mutations, including those with brain metastases.
The ongoing Phase 1b study evaluated its safety and antitumor activity in patients with locally advanced or metastatic disease.
As of September 4, 2026, data from 26 patients showed a confirmed systemic objective response ra...